# Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.

Study · id `cardio:ct-nct02555111` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02555111](<https://clinicaltrials.gov/study/NCT02555111>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02555111

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

## Technical summary

Registry record NCT02555111. Randomized; no masking; primary purpose treatment. Start 2015-09 (actual); primary completion 2020-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT02555111, source copy `cardio:ctgov-nct02555111-2022-07-26`, retrieved 2026-10-31)
- Started: 2015-09 (actual) (ClinicalTrials.gov record NCT02555111, source copy `cardio:ctgov-nct02555111-2022-07-26`, retrieved 2026-10-31)
- Primary completion: 2020-02 (actual) (ClinicalTrials.gov record NCT02555111, source copy `cardio:ctgov-nct02555111-2022-07-26`, retrieved 2026-10-31)
- Completion: 2020-02 (actual) (ClinicalTrials.gov record NCT02555111, source copy `cardio:ctgov-nct02555111-2022-07-26`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT02555111, source copy `cardio:ctgov-nct02555111-2022-07-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02555111-2022-07-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
- Acronym: RIPORT
- Condition: Deep Vein Thrombosis
- Condition: Chronic Portal Vein Thrombosis
- Intervention (Drug): Xarelto
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record: Rivaroxaban (Xarelto) (`cardio:xarelto`)
- Registry intervention name is a brand that an FDA record in the corpus ties to this substance: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: 4a92e8a73c6eeecd18a356902af94ef94c0e409d1eab506adbd5d04224f1d510
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
